507 Discussion week 7

1

507 Discussion Week 5

Student’s Name

Institutional Affiliation

Course Number and Name

Instructor’s Name

Assignment Due Date

507 Discussion week 5 (Discussion Post and Case Study)

Pathophysiology, etiology, signs/symptoms, complications, and risk factors

Human immunodeficiency virus (HIV-1) is a retrovirus that mainly infects CD4+ T lymphocytes, macrophages and dendritic cells. Human immunodeficiency virus uses CD4 and the coreceptors CCR5 and CXCR4 to get into the cells. Human immunodeficiency virus puts its DNA into the host DNA. Human immunodeficiency virus causes the CD4 cell counts to fall and Human immunodeficiency virus weakens the adaptive immunity. I notice infection of Human immunodeficiency virus as a flu‑like syndrome. I see fever and muscle aches in the patients first. After the flu‑like stage Human immunodeficiency virus moves into a latent phase that can last weeks or months. Human immunodeficiency virus finally brings about collapse. When HIV destroys the system the HIV destruction leads to severe opportunistic infections AIDS-defining malignancies organ damage and the HIV destruction can cause permanent damage if the HIV destruction is not treated. I have seen that HIV causes complications such as Pneumocystis jirovecii pneumonia, tuberculosis and Kaposi sarcoma (Swinkels et al. 2024). Researchers have identified risk factors for HIV such as sexual contact sharing injection equipment, perinatal exposure and transfusion of contaminated blood (WHO, 2024). HIV attacks the system and the HIV attack makes the body more vulnerable, to infections.

Diagnosis (assessment findings, labs, imaging)

The diagnosis starts by looking at symptoms such as fever, swollen lymph nodes, thrush and weight loss that has no reason. The diagnosis then moves to a laboratory test that uses a generation antigen/antibody assay to detect p24 antigen. Hiv antibodies. A reactive result moves the diagnosis to an HIV-1/HIV-2 differentiation assay. The diagnosis often includes acid testing (NAT), for HIV RNA measurement. The diagnosis confirms infection by checking the load. I follow the CDC guidelines. I order the baseline labs for ART initiation. The baseline labs for ART initiation are the CD4+ T‑cell count, the load, the complete blood count the liver function test, the renal function test and the genotype resistance test. I order a chest X‑ray, a CT scan or an MRI when I suspect PCP or TB. I use infection panels when infection panels are needed. I monitor the load over time to see how the antiretroviral therapy works. I look for a viral load, as proof that the antiretroviral therapy is effective.

Lifespan considerations (pediatric, pregnant/breastfeeding, older adults)

HIV acts differently across ages. In the newborns getting worse quickly happens because the newborns have a defense system. The early testing and the quick start of treatment improve health. Lower the chance of getting sick for the newborns. I have seen that the early testing and the quick start of treatment make a difference for the newborns. Mother’s virus amount during pregnancy makes passing the virus likely but ART can cut that risk a lot. Infants who might have been exposed get medicine. Breastfeeding can raise the chance of passing the virus if there is no other way to feed. The WHO guidelines try to balance the risks, with what the infant needs. I have seen adults with HIV management face these issues. The older adults have health problems, many medicines and an aging immune system. The ongoing inflammation in adults can cause metabolism problems and thinking problems. The health team needs custom screening for adults. The health team needs to check how ART is tolerated in adults. The health team needs to handle health problems, in older adults based on the age of the older adults and whether the older adults can have children.

Case Study

Final diagnosis

· Newly diagnosed HIV-1 infection, advanced immunosuppression (CD4 210 cells/µL) with high HIV-1 RNA (220,000 copies/mL); pulmonary process suspicious for opportunistic infection (PCP) pending microbiologic confirmation.

Patient identification

· Name: M.T.

· Age: 36 years.

· Sex: Male (white).

· Occupation: Independent construction contractor.

· Marital/social background: Divorced two years ago; co-parenting relationship with ex-wife. Limited local social support; occasional contact with an older brother who lives out of state.

Presenting complaint (what brought him to care)

· Patient reports a six‑week history of fatigue with low fevers and night sweats. Patient lost eight pounds without trying and reports a two‑week history of a dry cough that is getting worse and shortness of breath when the patient moves. The patient also reports white patches, in the mouth.

History of present illness and risk behaviors

· Patient reported that the symptoms began slowly and got worse over weeks. The patient reported inconsistent condom use in prior relationships and two brief sexual partners in the past year. Patient denied injection drug use but admitted heavy drinking. Patient reported delayed care was due to work and lack of paid leave.

Symptoms and physical exam findings

· Temperature 37.9°C, pulse 98 bpm, RR 20/min, oxygen saturation 94% on room air at rest.

· Oral thrush (white adherent plaques on the tongue and buccal mucosa), bilateral cervical and axillary lymphadenopathy, and mild intercostal retractions on deep inspiration. Scattered inspiratory crackles at the lung bases. No focal neurologic deficits.

Initial point-of-care and clinic testing

· Fourth-generation HIV antigen/antibody test: reactive.

· Rapid pregnancy test: not applicable (male).

· Point-of-care glucose and urine dipstick: normal.

Baseline laboratories and imaging ordered

· CBC with differential, CMP, CD4+ T-cell count, quantitative HIV-1 RNA (viral load), HIV-1/HIV-2 differentiation assay, genotype resistance testing, hepatitis B surface antigen and core antibody, hepatitis C antibody, syphilis serology, urine drug screen, and arterial blood gas if oxygenation worsens.

· Chest x-ray ordered for cough and hypoxia evaluation.

Key laboratory and imaging results (returned)

· CD4+ count: 210 cells/µL (reference 500–1,500).

· HIV-1 RNA: 220,000 copies/mL.

· CBC: mild normocytic anemia (Hgb 11.0 g/dL).

· CMP: mild transaminase elevation (ALT and AST ~1.4× ULN); creatinine within normal limits.

· Hepatitis B surface antigen: negative; Hepatitis C antibody: negative.

· Syphilis RPR: nonreactive.

· Chest x-ray: bilateral, diffuse, perihilar interstitial infiltrates more prominent centrally — radiographic pattern concerning for Pneumocystis jirovecii pneumonia (PCP) or atypical/viral pneumonitis.

Microbiology and confirmatory testing

· HIV-1/HIV-2 differentiation assay sent to reference lab; nucleic acid testing (HIV RNA NAT) ordered to clarify an acute vs established infection if differentiation unclear.

· Sputum induction and/or bronchoalveolar lavage planned for PCP stain and PCR; sputum GeneXpert ordered to screen for Mycobacterium tuberculosis given regional prevalence and risk.

Relevant past medical and surgical history

· No chronic medical conditions previously diagnosed. No prior hospitalizations or surgeries. No known prior opportunistic infections. Immunizations in adulthood incomplete due to inconsistent primary care access.

Medications and allergies

· No current prescription medications. No known drug allergies.

Clinical interpretation and rationale (worked backward to diagnosis)

· A reactive fourth-generation test along with very high HIV RNA and a CD4 count near 210 suggest confirmed HIV infection with considerable immune deficiency. Clinical symptoms such as oral thrush, persistent cough, weight loss, and interstitial infiltrates correspond with the risk of opportunistic infections (with PCP as a primary differential). His social factors (postponed treatment, unprotected intercourse) heightened the risk of contracting HIV and delaying diagnosis.

Management plan & rationale

· Confirmatory testing: Expedited differentiation assay. Confirmatory testing considers a repeat NAT if it is needed.

· Immediate ART initiation: Talk about and start a regimen based on integrase inhibitors (for example: dolutegravir combined with tenofovir and lamivudine) after reviewing baseline labs and obtaining a genotype resistance testing sample; prompt ART lowers morbidity and transmission risk.

· Opportunistic infection management: initiate TMP‑SMX right away for suspected PCP due to the chest X‑ray and symptoms matching. Administer steroids when the PaO₂ is under 70 mmHg or the A‑a gradient indicates moderate to low oxygen levels. Organize a sputum sample or a BAL sample to validate PCP.

· Prophylaxis and screenings: Provide continuous PCP prophylaxis if CD4 stays below 200, assess for latent TB and other opportunistic infections as needed, and update necessary vaccinations according to guidelines (inactivated influenza, pneumococcal as per adult HIV recommendations).

· Supportive care and linkage: Offer counseling for adherence, connection to HIV case management, help with insurance/ADAP applications, screening for mental health and substance use, and resources for partner notification.

· Follow-up monitoring: Repeat viral load and CD4 at 4–8 weeks after ART initiation, and at regular intervals thereafter to document viral suppression and immune recovery.

Prognosis and teaching points

· With prompt ART initiation, treatment of possible PCP, and social support to maintain adherence, Michael has a strong chance of achieving viral suppression and immune reconstitution. Addressing barriers like unstable insurance, transportation, and stigma is critical to long-term retention in care and improved outcomes.

References

Centers for Disease Control and Prevention. (2024). Getting tested for HIV. National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Division of HIV Prevention. https://www.cdc.gov/hiv/testing/index.html

HIV.gov. (2024). Understanding your HIV test results. U.S. Department of Health and Human Services. https://www.hiv.gov/hiv-basics/hiv-testing/learn-about-hiv-testing/understanding-hiv-test-results

Swinkels, H. M., Nguyen, A. D., & Gulick, P. G. (2024). HIV and AIDS. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK534860/

World Health Organization (WHO). (2024). HIV/AIDS—Key facts. https://www.who.int/health-topics/hiv-aids